Extended duration strategies for the pharmacologic treatment of diabetic retinopathy: current status and future prospects

Expert Opinion on Drug Delivery

Volumn 13, Issue 9, 2016, Pages 1277-1287

  Stewart, Michael W ^a   Flynn, Harry W ^b   Schwartz, Stephen G ^b   Scott, Ingrid U ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Aflibercept; bevacizumab; corticosteroids; diabetic macular edema; ranibizumab; sustained release devices; vascular endothelial growth factor

Indexed keywords

ABICIPAR PEGOL; AFLIBERCEPT; ALG 001; BEVACIZUMAB; BROLUCIZUMAB; DANAZOL; DEXAMETHASONE; DICLOFENAC; EGP 37; FASUDIL; FLUOCINOLONE ACETONIDE; KVD 001; LOTEPREDNOL ETABONATE; MINOCYCLINE; NESVACUMAB; OCRIPLASMIN; PAN 90806; RANIBIZUMAB; RAPAMYCIN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; FLUOCINOLONE; GLUCOCORTICOID; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

CELL ENCAPSULATION; CHORIORETINOPATHY; CORTICOSTEROID THERAPY; DIABETIC MACULAR EDEMA; DRUG DELIVERY SYSTEM; HUMAN; IMPLANTABLE PUMP; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROLIFERATIVE DIABETIC RETINOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUSTAINED DRUG RELEASE; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DIABETIC RETINOPATHY; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA;

DIABETIC RETINOPATHY; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84983261398     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1080/17425247.2016.1198771     Document Type: Review

References (82)

1. J.Sepúlveda, C.Murray The state of global health in 2014. Science. 2014;345:1275–1278.
2. D.S.Fong, L.P.Aiello, F.L.Ferris3rd, et al. Diabetic retinopathy. Diabetes Care. 2004;27:2540e53.
3. J.H.Kempen, B.J.O’Colmain, M.C.Leske, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122:552–563.
4. K.M.V.Narayan, J.P.Boyle, L.S.Geiss, et al. Impact of recent increase in incidence on future diabetes burden:U.S., 2005–2050. Diabetes Care. 2006;29:2114–2116.
5. D.M.Brown, Q.D.Nguyen, D.M.Marcus, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema:the 36-month results from two phase III trials:RISE and RIDE. Ophthalmology. 2013;120:2013–2022.•• The 3-year results of the phase III ranibizumab registration trials provide the ‘gold standard’ against which most DME trials are compared.
6. D.M.Brown, U.Schmidt-Erfurth, D.V.Do, et al. Intravitreal aflibercept for diabetic macular edema:100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122:2044–2052.• Two-year results of the phase III aflibercept registration trials were instrumental in achieving FDA approval for the treatment of DME.
7. Diabetic Retinopathy Clinical Research Network, M.J.Elman, N.M.Bressler, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–614.
8. Diabetic Retinopathy Clinical Research Network, J.A.Wells, A.R.Glassman, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–1203.•• The DRCR.net Protocol T trial has been the only multi-center, randomized head-to-head trial of the three anti-VEGF drugs.
9. P.J.Rosenfeld, D.M.Brown, J.S.Heier, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431.
10. D.M.Brown, P.K.Kaiser, M.Michels, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444.
11. J.S.Heier, D.M.Brown, V.Chong, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–2548.
12. J.Jonas, A.Sofker. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001;132:425–427.
13. A.Martidis, J.S.Duker, P.B.Greenberg, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920–927.
14. T.W.Gardner, D.A.Antonetti, A.J.Barber, et al. New insights into the pathophysiology of diabetic retinopathy:potential cell-specific therapeutic targets. Diabetes Technol Ther. 2000;2:601–608.
15. X.Zhang, N.Wang, A.P.Schachat, et al. Glucocorticoids:structure, signaling and molecular mechanisms in the treatment of diabetic retinopathy and diabetic macular edema. Curr Mol Med. 2014;14:376–384.
16. A.Nehmé, E.K.Lobenhofer, W.D.Stamer, et al. Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics. 2009;2:58.
17. P.M.Beer, S.J.Bakri, R.J.Singh, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681–686.
18. Diabetic Retinopathy Clinical Research Network (DRCR.net), R.W.Beck, A.R.Edwards, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127:245–251.
19. S.B.Bressler, A.R.Glassman, T.Almukhtar, et al. Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema. Am J Ophthalmol. 2016;164:57–68.
20. N.Ferrara, L.Damico, N.Shams, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859–870.
21. T.U.Krohne, Z.Liu, F.G.Holz, et al. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012;154:682–686.
22. L.Xu, T.Lu, L.Tuomi, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration:a population approach. Invest Ophthalmol Vis Sci. 2013;54:1616–1624.
23. N.Papadopoulos, J.Martin, Q.Ruan, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–185.
24. J.Lowe, J.Araujo, J.Yang, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res. 2007;85:425–430.
25. R.L.Avery, A.A.Castellarin, N.C.Steinle, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98:1636–1641.
26. A.C.Ho, I.U.Scott, S.J.Kim, et al. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema:a report by the American Academy of Ophthalmology. Ophthalmology. 2012;119(10):2179–2188.
27. P.Massin, F.Bandello, J.G.Garweg, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study):a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399–2405.
28. P.Mitchell, F.Bandello, U.Schmidt-Erfurth, et al. The RESTORE study:ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–625.
29. G.E.Lang, A.Berta, B.M.Eldem, et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema:interim analysis of the RESTORE extension study. Ophthalmology. 2013;120:2004–2012.
30. U.Schmidt-Erfurth, G.E.Lang, F.G.Holz, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema:the RESTORE extension study. Ophthalmology. 2014;121:1045–1053.
31. Q.D.Nguyen, D.M.Brown, D.M.Marcus, et al. Ranibizumab for diabetic macular edema:results from 2 phase III randomized trials:RISE and RIDE. Ophthalmology. 2012;119:789–801.
32. D.S.Boyer, Q.D.Nguyen, D.M.Brown, et al. Outcomes with as-needed ranibizumab after initial monthly therapy:long-term outcomes of the phase III RIDE and RISE trials. Ophthalmology. 2015;122:2504–2513.
33. Diabetic Retinopathy Clinical Research Network, M.J.Elman, L.P.Aiello, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–1077.
34. Diabetic Retinopathy Clinical Research Network, M.J.Elman, H.Qin, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment:three-year randomized trial results. Ophthalmology. 2012;119:2312–2318.•• The DRCR.net Protocol I trial provided the first data directly comparing ranibizumab with prompt or deferred laser against laser/sham and triamcinolone with prompt laser.
35. M.J.Elman, A.Ayala, N.M.Bressler, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment:5-year randomized trial results. Ophthalmology. 2015;122:375–381.
36. FDA approval for bevacizumab [Internet]. [cited 2016 Jan28]. Available from:http://www.cancer.gov/about-cancer/treatment/drugs/fda-bevacizumab
37. T.U.Krohne, N.Eter, F.G.Holz, et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;146:508–512.
38. L.G.Presta, H.Chen, S.J.O’Connor, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593–4599.
39. J.Mordenti, R.A.Cuthbertson, N.Ferrara, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27:536–544.
40. P.J.Rosenfeld, A.A.Moshfeghi, C.A.Puliafito. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331–335.
41. P.J.Rosenfeld, A.E.Fung, C.A.Puliafito. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:336–339.
42. N.M.Bressler, A.R.Edwards, A.N.Antoszyk, et al. Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol. 2008;145:894–901.
43. R.Rajendram, S.Fraser-Bell, A.Kaines, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema:24-month data:report 3. Arch Ophthalmol. 2012;130:972–979.
44. J.Holash, S.Davis, N.Papadopoulos, et al. VEGF-Trap:a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99:11393–11398.
45. E.Furfine, A.Coppi, E.Koehler-Stec, et al. Pharmacokinetics and ocular tissue penetration of VEGF Trap after intravitreal injections in rabbits. Invest Ophthalmol Vis Sci. 2006;47:E–abstract 1430.
46. J.E.Chang-Lin, M.Attar, A.A.Acheampong, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80–86.
47. B.D.Kuppermann, M.S.Blumenkranz, J.A.Haller, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125:309–317.
48. J.A.Haller, B.D.Kuppermann, M.S.Blumenkranz, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128:289–296.
49. D.S.Boyer, Y.H.Yoon, R.BelfortJr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–1914.• Data from the 3-year phase III dexamethasone insert registration trials led to FDA approval of the insert for the treatment of DME.
50. P.A.Pearson, T.L.Comstock, M.Ip, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema:a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology. 2011;118:1580–1587.
51. P.A.Campochiaro, D.M.Brown, A.Pearson, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–2132.• Data from the 3-year phase III fluocinolone insert registration trial led to FDA approval of the insert for eyes with DME that do not develop an increased intraocular pressure when treated with corticosteroids.
52. J.Cunha-Vaz, P.Ashton, R.Iezzi, et al. Sustained delivery fluocinolone acetonide vitreous implants:long-term benefit in patients with chronic diabetic macular edema. Ophthalmology. 2014;121:1892–1903.
53. P.A.Campochiaro, Q.D.Nguyen, G.Hafiz, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120:583–587.
54. P.A.Campochiaro, R.Channa, B.B.Berger, et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor:a phase I/II study. Am J Ophthalmol. 2013;155:697–704.
55. ClinicalTrials.gov Identifier:NCT02462486 [Internet]. [cited 2016 Jan24]. Available from:https://clinicaltrials.gov/ct2/show/NCT02462486
56. Novel anti-VEGF agent may provide important advancement in AMD treatment [Internet]. [cited 2016Jan28]. Available from:http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/news/novel-anti-vegf-agent-may-provide-important-advancement-amd-treatment?page=full
57. Long-acting anti-VEGF delivery [Internet]. [cited 2016Jan15]. Available from:http://retinatoday.com/2014/08/long-acting-anti-vegf-delivery
58. M.Humayan, A.Santos, J.C.Altamirano, et al. Implantable micropump for drug delivery in patients with diabetic macular edema. Transl Vis Sci Technol. 2014;3(6):5.eCollection2014.
59. K.Kauper, C.McGovern, S.Sherman, et al. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest Ophthalmol Vis Sci. 2012;53:7484–7491.
60. ClinicalTrials.gov identifier:NCT02228304 [Internet]. [cited 2016 Jan24]. Available from:https://clinicaltrials.gov/ct2/show/NCT02228304
61. FDA advisory to Ampio Pharmaceuticals. [cited 2015 Oct23]. Available from:http://campaign.r20.constantcontact.com/render?ca=6f759dbd-431a-417b-94b1-bfd8be310ff7&c=de0e4120-b64d-11e3-bf1e-d4ae527b6fccχdeced200-b64d-11e3-bf7e-d4ae527b6fcc
62. J.K.Krady, A.Basu, C.M.Allen, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005;54:1559–1565.
63. H.Y.Zeng, W.R.Green, M.O.Tso. Microglial activation in human diabetic retinopathy. Arch Ophthalmol. 2008;126:227–232.
64. D.Gaucher, J.A.Chiappore, M.Paques, et al. Microglial changes occur without neural cell death in diabetic retinopathy. Vision Res. 2007;47:612–623.
65. M.E.Ryan, A.Usman, N.S.Ramamurthy, et al. Excessive matrix metalloproteinase activity in diabetes:inhibition by tetracycline analogues with zinc reactivity. Curr Med Chem. 2001;8:305–316.
66. M.E.Ryan, N.S.Ramamurthy, L.M.Golub. Tetracyclines inhibit protein glycation in experimental diabetes. Adv Dent Res. 1998;12:152–158.
67. R.G.Craig, Z.Yu, L.Xu, et al. A chemically modified tetracycline inhibits streptozotocin-induced diabetic depression of skin collagen synthesis and steady-state type I procollagen mRNA. Biochim Biophys Acta. 1998;1402:250–260.
68. A.L.Wang, A.C.Yu, L.T.Lau, et al. Minocycline inhibits LPS-induced retinal microglia activation. Neurochem Int. 2005;47(1–2):152–158.
69. T.J.Federici. The non-antibiotic properties of tetracyclines:clinical potential in ophthalmic disease. Pharmacol Res. 2011;64:614–623.
70. K.G.Falavarjani, A.Pourhabibi, K.A.Aghdam, et al. Determination of the toxicity of intravitreal minocycline in rabbit eyes. Cutan Ocul Toxicol. 2015 Sep 11:1–4. [Epub ahead of print]
71. I.U.Scott, G.R.Jackson, D.A.Quillen, et al. Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in patients with severe nonproliferative or non–high-risk proliferative diabetic retinopathy:a randomized clinical trial. JAMA Ophthalmol. 2014;132(5):535–543.
72. I.U.Scott, G.R.Jackson, D.A.Quillen, et al. Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in mild to moderate nonproliferative diabetic retinopathy. A randomized proof-of-concept clinical trial. JAMA Ophthalmol. 2014;132:1137–1142.
73. C.A.Cukras, P.Petrou, E.Y.Chew, et al. Oral minocycline for the treatment of diabetic macular edema (DME):results of a phase I/II clinical study. Invest Ophthalmol Vis Sci. 2012;53:3865–3874.
74. Topical loteprednol for the treatment of DME. [cited 2015 Oct20]. Available from:http://www.marketwatch.com/story/kala-pharmaceuticals-initiates-phase-2-clinical-trial-to-evaluate-le-mpp-kpi-121-in-patients-with-retinal-vein-occlusion-and-diabetic-macular-edema-2014-07-31
75. Eyegate announces interim data from phase 1b / 2a clinical trial of iontophoretic EGP-437 ophthalmic solution in macular edema patients [Internet]. [cited 2015Nov24]. Available from:http://www.eyegatepharma.com/uncategorized/eyegate-announces-interim-data-from-phase-1b-2a-clinical-trial-of-iontophoretic-egp-437-ophthalmic-solution-in-macular-edema-patients/
76. Panoptica reports progress with PAN-90806, a topical anti-VEGF eyedrop for the treatment of neovascular (Wet) AMD [Internet]. [cited 2015Nov22]. Available from:http://www.businesswire.com/news/home/20151112005385/en/PanOptica-Reports-Progress-PAN-90806-Topical-Anti-VEGF-Eyedrop
77. M.Soheilian, S.Karimi, A.Ramezani, et al. Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema:a randomized double-masked clinical trial. Int Ophthalmol. 2015 Jun;35(3):421–428.
78. N.Krishnadev, F.Forooghian, C.Cukras, et al. Subconjunctival sirolimus in the treatment of diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2011;249:1627–1633.
79. R.Nourinia, H.Ahmadieh, M.H.Shahheidari, et al. Intravitreal fasudil combined with bevacizumab for treatment of refractory diabetic macular edema; a pilot study. J Ophthalmic Vis Res. 2013;8:337–340.
80. Allegro ophthalmics announces last patient enrolled in del mar phase 2b clinical trial of luminate® for the treatment of diabetic macular edema [Internet]. [cited 2016Jan10]. Available from:http://www.allegroeye.com/press-release/allegro-ophthalmics-announces-last-patient-enrolled-in-del-mar-phase-2b-clinical-trial-of-luminate-for-the-treatment-of-diabetic-macular-edema/#sthash.YKXN8VQd.dpuf
81. KalVista Pharmaceuticals web site. [cited 2013 May21]. Available from:http://www.kalvista.com/news/37/131/KalVista-Pharmaceuticals-Wins-2-4m-Bio-medical-Catalyst-Grant-to-Further-Develop-Oral-Plasma-Kallikrein-Inhibitors-as-a-Treatment-for-Diabetic-Macular-Edema.html
82. ClinicalTrials.gov Identifier:NCT01997164 [Internet]. [cited 2016 Jun 16]. Available form:https://clinicaltrials.gov/ct2/show/NCT01997164